GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Net-Net Working Capital

Inoviq (ASX:IIQ) Net-Net Working Capital : A$0.07 (As of Jun. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Inoviq's Net-Net Working Capital for the quarter that ended in Jun. 2024 was A$0.07.

The industry rank for Inoviq's Net-Net Working Capital or its related term are showing as below:

ASX:IIQ's Price-to-Net-Net-Working-Capital is ranked worse than
63.74% of 91 companies
in the Medical Diagnostics & Research industry
Industry Median: 4.95 vs ASX:IIQ: 7.50

Inoviq Net-Net Working Capital Historical Data

The historical data trend for Inoviq's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Net-Net Working Capital Chart

Inoviq Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.01 0.14 0.07 0.07

Inoviq Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.10 0.07 0.05 0.07

Competitive Comparison of Inoviq's Net-Net Working Capital

For the Diagnostics & Research subindustry, Inoviq's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inoviq's Price-to-Net-Net-Working-Capital Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Inoviq's Price-to-Net-Net-Working-Capital falls into.



Inoviq Net-Net Working Capital Calculation

Inoviq's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2024 is calculated as

Net-Net Working Capital(A: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(9.233+0.75 * 0.027+0.5 * 0.018-1.719
-0-0)/105.519
=0.07

Inoviq's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(9.233+0.75 * 0.027+0.5 * 0.018-1.719
-0-0)/105.519
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Inoviq  (ASX:IIQ) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Inoviq Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Inoviq's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Inoviq Business Description

Traded in Other Exchanges
N/A
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq Headlines

No Headlines